346: Zealand's obesity strategy and Immunovant's curious development plan
The Readout Loud
00:00
Navigating Gene Therapy Controversies
This chapter explores a company's controversial decision to withhold their first-generation product while also addressing the serious implications of a teenager's death linked to a gene therapy for Duchenne muscular dystrophy. It raises urgent questions regarding the regulatory landscape, safety concerns, and the complexities of administering treatments to vulnerable patients.
Transcript
Play full episode
